OptiBiotix Health (OPTI)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

17.75p
   
  • Change Today:
    -0.25p
  • 52 Week High: 39.00
  • 52 Week Low: 6.00
  • Currency: UK Pounds
  • Shares Issued: 97.94m
  • Volume: 0
  • Market Cap: £17.38m

OptiBiotix to launch SlimBiome Medical in UK market this month

By Josh White

Date: Wednesday 24 Apr 2019

LONDON (ShareCast) - (Sharecast News) - Life sciences business OptiBiotix Health announced the launch of its weight management product 'SlimBiome Medical' to the UK market on Wednesday.
The AIM-traded firm said SlimBiome Medical, which is a CE-marked medical device, offered a "healthy, hunger-free" weight management solution designed for use by itself, or as part of a calorie-restricted diet, to reduce hunger and help users achieve sustainable weight loss.

Independent clinical studies showed SlimBiome reduced hunger, cravings for sweet and savoury foods, and fat intake.

It would be available in boxes of 30 single dose sachets, and for purchase from the company's online store, from 29 April.

The board said the commercial launch followed its announcement that SlimBiome was granted medical device status and a CE-mark in November, as well as the appointment of Nutrilinea as a manufacturer in the same month, and three-year distribution agreements for Greece and Cyprus in December and Bulgaria in April.

OptiBiotix also reported pre launch sales of SlimBiome Medical to Bridge4 Health - a "unique" health and wellbeing centre based in Leicester.

Bridge4 Health would conduct a three-month SlimBiome Medical field trial involving its gym members to support healthy sustained weight loss.

The early deals and sales orders so soon after achieving medical device registration reflected the "high level" of interest received in the product from an industry which recognised the value of products with "strong science" and published human studies, the board explained.

It added that the online sale of SlimBiome Medical as a final product was another example of OptiBiotix's strategy of building multiple revenue streams from ingredient sales, white label and own label branded consumer products, across multiple sales channels.

The channel would provide a new route to market for SlimBiome, allowing the firm to generate immediate revenues while building sales with international and retail partners from SlimBome as an ingredient, medical device, and in white label or branded 'GoFigure' final products.

OptiBiotix said it anticipated further commercial agreements for SlimBiome, SlimBiome Medical, and GoFigure products in international markets in the months ahead.

"SlimBiome Medical is a innovative product transforming the way weight loss is traditionally approached as it delivers a sustainable, science-backed weight control system which offers dieters additional support to sustain and/or maintain weight loss," said managing director of the OptiBiotix prebiotics division Fred Narbel.

"We are delighted to be able to bring this product to the UK market through our online store which allows us to build early revenues at high margin through direct to consumer sales."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OPTI Market Data

Currency UK Pounds
Share Price 17.75p
Change Today -0.25p
% Change -1.39 %
52 Week High 39.00
52 Week Low 6.00
Volume 0
Shares Issued 97.94m
Market Cap £17.38m

OPTI Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
60.16% above the market average60.16% above the market average60.16% above the market average60.16% above the market average60.16% above the market average
92.16% above the sector average92.16% above the sector average92.16% above the sector average92.16% above the sector average92.16% above the sector average
Price Trend
16.42% below the market average16.42% below the market average16.42% below the market average16.42% below the market average16.42% below the market average
33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average
Income Not Available
Growth
96.72% below the market average96.72% below the market average96.72% below the market average96.72% below the market average96.72% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average

OPTI Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

OPTI Key Personnel

CEO Stephen O'Hara
Finance Director Graham Myers

Top of Page